Ruiwen Zhang

Professor Ruiwen Zhang is a faculty member in the Department of Pharmacological and Pharmaceutical Sciences at the University of Houston College of Pharmacy, where he focuses on cancer therapy through targeting tumor suppressors and oncogenes. His work spans preclinical evaluation of therapeutics and clinical pharmacology, integrating molecular biology with pharmacological innovation.

Education:

• Ph.D. in Toxicology and Occupational Epidemiology, Fudan University Shanghai Medical College
• M.D., Fudan University Shanghai Medical College
• Postdoctoral Fellowship in Clinical Pharmacology, University of Alabama School of Medicine

His research highlights the development of MDM2 inhibitors, antisense oligonucleotides, and dual-targeting agents for cancers including neuroblastoma, pancreatic, and breast tumors. Key trends include apoptosis regulation, oncogene suppression, and translational pharmacology.

Scientific Awards:

• Fellow, American Association for the Advancement of Science (AAAS), 2009-present
• Fellow, National Academy of Inventors (NAI), 2018-present
• Board-certified toxicologist, American Board of Toxicology, 1999-present

As a board-certified toxicologist and experienced researcher, Zhang has significantly contributed to pharmacological cancer therapy, with a strong emphasis on preclinical validation and molecular mechanism elucidation.